Get started
Apimeds Pharmaceuticals US, Inc.Apimeds Pharmaceuticals US, Inc.Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc.

No trades
See on Supercharts
Overview
Financials Discussions Seasonals

APUS chart


Full chart

Key stats


Market capitalization
‪25.73 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.11 USD
Net income (FY)
‪−1.39 M‬ USD
Revenue (FY)
0.00 USD
Shares float
—
Beta (1Y)
—

Employees


Employees (FY)
2
Change (1Y)
0
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−695.00 K‬ USD

About Apimeds Pharmaceuticals US, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Erik Emerson
Website
apimedspharmaus.com
Headquarters
Hopewell
Founded
2020
FIGI
BBG01Q0T3D78
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Hopewell, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as APUS.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Apimeds Pharmaceuticals US, Inc. stocks are traded under the ticker APUS.
APUS stock has fallen by −45.00% compared to the previous week, the month change is a −45.00% fall, over the last year Apimeds Pharmaceuticals US, Inc. has showed a −45.00% decrease.
Yes, you can track Apimeds Pharmaceuticals US, Inc. financials in yearly and quarterly reports right on TradingView.
APUS net income for the last quarter is ‪−311.63 K‬ USD, while the quarter before that showed ‪−332.52 K‬ USD of net income which accounts for 6.28% change. Track more Apimeds Pharmaceuticals US, Inc. financial stats to get the full picture.
No, APUS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 10, 2025, the company has 2 employees. See our rating of the largest employees — is Apimeds Pharmaceuticals US, Inc. on this list?
Like other stocks, APUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Apimeds Pharmaceuticals US, Inc. stock right from TradingView charts — choose your broker and connect to your account.